Trade Summary

11 months ago, Flynn James E, serving as * Director by Deputization, 10% owner at Larimar Therapeutics, Inc. (LRMR), purchased 9,375,000 shares at $3.20 per share, for a total transaction value of $30,000,000.00. Following this transaction, Flynn James E now holds 30,606,974 shares of LRMR.

This purchase represents a 44.00% increase in Flynn James E's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, July 31, 2025 and publicly disclosed via SEC Form 4 filing on Monday, August 4, 2025 at 6:28 PM ET, 4 days after the trade was made.

Larimar Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.